building a national capability to monitor and assess public health emergency medical countermeasure (MCM) use after dispensing/administration during public health emergencies. The workshop will focus ...

BIO 300 will be the subject of a presentation at a U.S. industry, national security, and healthcare forum on February 27th, 2025.

During the meeting, Tevogen Bio discussed ExacTcell’s unique ability to rapidly adapt to emerging viral threats, positioning it as a potential countermeasure to safeguard public health.